Form 4: Werewolf Therapeutics Director Sells Shares

Werewolf Therapeutics Director Luke Evnin sold 38,782 shares of common stock at a weighted average price of $0.54 per share, executed under a pre-arranged 10b5-1 plan.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), reported the sale of 38,782 shares of common stock.
• The transaction occurred on January 16, 2026, at a weighted average price of $0.54 per share.
• The shares were sold in multiple transactions with prices ranging from $0.535 to $0.5495.
• This sale was executed pursuant to a Rule 10b5-1 trading plan established on September 24, 2025.
• Following the transaction, Luke Evnin's indirect beneficial ownership stands at 2,159,860 shares.
• The shares are held indirectly through various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.

Sentiment

Score: 4

Explanation: The sale of shares by a director is generally a negative signal, but the execution under a pre-arranged 10b5-1 plan mitigates the immediate negative sentiment, making it more neutral to slightly negative. The low share price of the sale is also a factor.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a scheduled sale rather than a reaction to immediate company news.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the director's direct or indirect stake in the company.
• The sale price of $0.54 per share is relatively low, potentially reflecting a lower valuation for the company's stock.

Risks

• While a 10b5-1 plan mitigates the signal, a director selling shares could be perceived by some investors as a lack of confidence in the company's near-term prospects, potentially impacting investor sentiment.

Related Party Transactions

• The sale involved shares held by various MPM entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.) where Luke Evnin has affiliations (member, Managing Director, manager), making these entities related parties to the reporting person.

Stakeholder Impact

• Shareholders may interpret the director's sale, even under a 10b5-1 plan, as a slight negative signal, potentially impacting investor confidence.
• The company's market perception could be influenced by the insider transaction, though it does not directly impact operations or financials.

Key Dates

Recommendation

While an insider sale can be a negative signal, this transaction was pre-scheduled under a 10b5-1 plan, reducing its immediate interpretative impact on company prospects. The sale at $0.54 per share is a data point, but without further financial or operational context from other filings, a 'hold' recommendation is prudent, awaiting more comprehensive information to assess the company's fundamental value and future trajectory.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Sale, Form 4, SEC Filing, 10b5-1 Plan, Director Transaction, Equity Sale, Biotechnology